A randomized, placebo-controlled phase 2 study of ganitumab or conatumumab in combination with FOLFIRI for second-line treatment of mutant KRAS metastatic colorectal cancer

Annals of Oncology

Volumn 24, Issue 7, 2013, Pages 1777-1785

  Cohn, A L ^a   Tabernero, J ^b   Maurel, J ^c   Nowara, E ^d   Sastre, J ^e,f   Chuah, B Y S ^g   Kopp, M V ^h   Sakaeva, D D ⁱ   Mitchell, E P ^j   Dubey, S ^k   Suzuki, S ^k   Hei, Y J ^k   Galimi, F ^k   McCaffery, I ^k   Pan, Y ^k   Loberg, R ^k   Cottrell, S ^k   Choo, S P ^l  

^a Rocky Mountain Cancer Center   (United States)

^b VALL D HEBRON UNIVERSITY HOSPITAL   (Spain)

^c HOSPITAL CLÍNIC   (Spain)

^d INSTITUTE OF ONCOLOGY   (Poland)

^e HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^f Ministry of Science and Innovation   (Spain)

^g NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^h Samara Regional Clinical Oncology Dispensary   (Russian Federation)

ⁱ Oncological Hospital of the Republic of Bashkortostan   (Russian Federation)

^j THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

^k AMGEN INC   (United States)

^l DIVISION OF MEDICAL ONCOLOGY   (Singapore)

more..

Author keywords

Conatumumab; FOLFIRI; Ganitumab; KRAS; Metastatic colorectal cancer

Indexed keywords

CONATUMUMAB; DEATH RECEPTOR 5; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; GANITUMAB; IRINOTECAN; OXALIPLATIN; PLACEBO; SOMATOMEDIN C;

ABDOMINAL PAIN; ADULT; ALOPECIA; ARTICLE; ASTHENIA; CANCER CHEMOTHERAPY; CHEMOTHERAPY INDUCED ANEMIA; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CHILL; CONSTIPATION; CONTINUOUS INFUSION; CONTROLLED STUDY; DECREASED APPETITE; DEHYDRATION; DIARRHEA; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; FATIGUE; FEMALE; FEVER; HUMAN; HUMAN TISSUE; HYPERGLYCEMIA; INTESTINE OBSTRUCTION; KRAS GENE; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; METASTATIC COLORECTAL CANCER; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; ONCOGENE; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RECTUM CARCINOMA; STOMATITIS; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 84883823174     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt057     Document Type: Article

References (42)

1. Cunningham D, Humblet Y, Siena S et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337-345.
2. Van Cutsem E, Peeters M, Siena S et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007; 25: 1658-1664.
3. Peeters M, Price TJ, Cervantes A et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol 2010; 28: 4706-4713.
4. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342.
5. Van Cutsem E, Tabernero J, Lakomy R et al. Intravenous (IV) aflibercept versus placebo in combination with irinotecan/5-FU (FOLFIRI) for second-line treatment of metastatic colorectal cancer (MCRC): results of a multinational phase III trial (EFC10262-VELOUR). Presented at: 13th World Congress on Gastrointestinal Cancer; June 22-25, 2011; Barcelona, Spain.
6. Grothey A, Sobrero AF, Siena S et al. Results of a phase III randomized, doubleblind, placebo-controlled, multicenter trial (CORRECT) or regorafenib plus best supportive care (BSC) in patients with metastatic colorectal cancer (mCRC) who have progressed after standard therapies. J Clin Oncol 2012; 30 (suppl): 385.
7. Amado RG, Wolf M, Peeters M et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26: 1626-1634.
8. Douillard JY, Siena S, Cassidy J et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 2010; 28: 4697-4705.
9. Karapetis CS, Khambata-Ford S, Jonker DJ et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008; 359: 1757-1765.
10. Bokemeyer C, Bondarenko I, Makhson A et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009; 27: 663-671.
11. Van Cutsem E, Köhne CH, Hitre E et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009; 360: 1408-1417.
12. Strater J, Hinz U, Walczak H et al. Expression of TRAIL and TRAIL receptors in colon carcinoma: TRAIL-R1 is an independent prognostic parameter. Clin Cancer Res 2002; 8: 3734-3740.
13. van Geelen CM, Westra JL, de Vries EG et al. Prognostic significance of tumor necrosis factor-related apoptosis-inducing ligand and its receptors in adjuvantly treated stage III colon cancer patients. J Clin Oncol 2006; 24: 4998-5004.
14. McLornan DP, Barrett HL, Cummins R et al. Prognostic significance of TRAIL signaling molecules in stage II and III colorectal cancer. Clin Cancer Res 2010; 16: 3442-3451.
15. Kaplan-Lefko PJ, Graves JD, Zoog SJ et al. Conatumumab, a fully human agonist antibody to death receptor 5, induces apoptosis via caspase activation in multiple tumor types. Cancer Biol Ther 2010; 9: 618-631.
16. Herbst RS, Kurzrock R, Hong DS et al. A first-in-human study of conatumumab in adult patients with advanced solid tumors. Clin Cancer Res 2010; 16: 5883-5891.
17. Hakam A, Yeatman TJ, Lu L et al. Expression of insulin-like growth factor-1 receptor in human colorectal cancer. Hum Pathol 1999; 30: 1128-1133.
18. Takahari D, Yamada Y, Okita NT et al. Relationships of insulin-like growth factor- 1 receptor and epidermal growth factor receptor expression to clinical outcomes in patients with colorectal cancer. Oncology 2009; 76: 42-48.
19. Flanigan SA, Pitts TM, Eckhardt SG et al. The insulin-like growth factor I receptor/insulin receptor tyrosine kinase inhibitor PQIP exhibits enhanced antitumor effects in combination with chemotherapy against colorectal cancer models. Clin Cancer Res 2010; 16: 5436-5446.
20. Ji QS, Mulvihill MJ, Rosenfeld-Franklin M et al. A novel, potent, and selective insulin-like growth factor-I receptor kinase inhibitor blocks insulin-like growth factor-I receptor signaling in vitro and inhibits insulin-like growth factor-I receptor dependent tumor growth in vivo. Mol Cancer Ther 2007; 6: 2158-2167.
21. Ii M, Li H, Adachi Y et al. The efficacy of IGF-I receptor monoclonal antibody against human gastrointestinal carcinomas is independent of k-ras mutation status. Clin Cancer Res 2011; 17: 5048-5059.
22. Beltran PJ, Mitchell P, Chung YA et al. AMG 479, a fully human anti-insulin-like growth factor receptor type I monoclonal antibody, inhibits the growth and survival of pancreatic carcinoma cells. Mol Cancer Ther 2009; 8: 1095-1105.
23. Beltran PJ, Chung YA, Moody G et al. Efficacy of ganitumab (AMG 479), alone and in combination with rapamycin, in Ewing's and osteogenic sarcoma models. J Pharmacol Exp Ther 2011; 337: 644-654.
24. Tolcher AW, Sarantopoulos J, Patnaik A et al. Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1. J Clin Oncol 2009; 27: 5800-5807.
25. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
26. Paz-Ares L, Sánchez Torres JM, Diaz-Padilla Iet al. Safety and efficacy of AMG 655 in combination with paclitaxel and carboplatin (PC) in patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2009; 27 (suppl): 19048.
27. Rosen LS, Puzanov I, Friberg G et al. Safety and pharmacokinetics of ganitumab (AMG 479) combined with sorafenib, panitumumab, erlotinib, or gemcitabine in patients with advanced solid tumors. Clin Cancer Res 2012; 18: 3414-3427.
28. Clopper CJ, Pearson ES. The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika 1934; 26: 404-413.
29. Pan Y, Haddad V, Sabin T et al. Predictive value of Fc gamma receptor IIIa genotype in response to conatumumab in three phase II studies. J Clin Oncol 2011; 29 (suppl): 3103.
30. Trarbach T, Moehler M, Heinemann V et al. Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer. Br J Cancer 2010; 102: 506-512.
31. Peeters M, Infante JR, Rougier P et al. Phase 1b/II trial of conatumumab and panitumumab (pmab) for the treatment (tx) of metastatic colorectal cancer (mCRC): safety and efficacy. Presented at: American Society of Clinical Oncology Gastrointestinal Cancers Symposium; January 22-24, 2010; Orlando, FL.
32. Becerra C, Salazar R, Garcia-Carbonero R et al. Phase II trial of figitumumab in patients with refractory, metastatic colorectal cancer (mCRC). J Clin Oncol 2011; 29 (suppl): 3525.
33. Lin EH, Lenz H, Saleh MN et al. A fixed-sequence, open-label study to determine the activity of SCH 717454 (robatumumab) as assessed by positron emission tomography in patients with relapse or recurrent colorectal cancer. J Clin Oncol 2011; 29 (suppl): 3584.
34. Watkins DJ, Tabernero J, Schmoll H et al. A randomized phase II/III study of the anti-IGF-1R antibody MK-0646 (dalotuzumab) in combination with cetuximab (Cx) and irinotecan (Ir) in the treatment of chemorefractory metastatic colorectal cancer (mCRC) with wild-type (wt) KRAS status. J Clin Oncol 2011; 29 (suppl): 3501.
35. Reidy DL, Vakiani E, Fakih MG et al. Randomized, phase II study of the insulinlike growth factor-1 receptor inhibitor IMC-A12, with or without cetuximab, in patients with cetuximab- or panitumumab-refractory metastatic colorectal cancer. J Clin Oncol 2010; 28: 4240-4246.
36. Leong S, Cohen RB, Gustafson DL et al. Mapatumumab, an antibody targeting TRAIL-R1, in combination with paclitaxel and carboplatin in patients with advanced solid malignancies: results of a phase I and pharmacokinetic study. J Clin Oncol 2009; 27: 4413-4421.
37. Soria JC, Mark Z, Zatloukal P et al. Randomized phase II study of dulanermin in combination with paclitaxel, carboplatin, and bevacizumab in advanced nonsmall- cell lung cancer. J Clin Oncol 2011; 29: 4442-4451.
38. Demetri GD, Le Cesne A, Chawla SP et al. First-line treatment of metastatic or locally advanced unresectable soft tissue sarcomas with conatumumab in combination with doxorubicin or doxorubicin alone: A Phase I/II open-label and double-blind study. Eur J Cancer 2012; 48: 547-563.
39. Kindler HL, Richards DA, Garbo LE et al. A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer. Ann Oncol 2012; 23: 2834-2842.
40. Jassem J, Lange CJ, Karp DD et al. Randomized, open label, phase III trial of figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin in patients with non-small cell lung cancer (NSCLC). J Clin Oncol 2010; 28 (suppl): 7500.
41. Asghar U, Hawkes E, Cunningham D. Predictive and prognostic biomarkers for targeted therapy in metastatic colorectal cancer. Clin Colorectal Cancer 2010; 9: 274-281.
42. McCaffery I Tudor Y, Deng H et al. Effect of baseline (BL) biomarkers on overall survival (OS) in metastatic pancreatic cancer (mPC) patients (pts) treated with ganitumab (GAN; AMG 479) or placebo (P) in combination with gemcitabine (G). J Clin Oncol 2011; 29 (suppl): 4041.